Michel Detheux, president and CEO of Iteos Therapeutics Inc., discusses what his company brings GSK in a massive new deal.   Hosted on Acast. See <a style="color: grey;" href="https://acast.com/privacy" target= "_blank" rel="noopener noreferrer">acast.com/privacy</a> for more information.

Michel Detheux, president and CEO of Iteos Therapeutics Inc., discusses what his company brings GSK in a massive new deal. Hosted on Acast. See acast.com/privacy for more information.

Michel Detheux, president and CEO of Iteos Therapeutics Inc., discusses what his company brings GSK in a massive new deal. &nbsp; Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer">acast.com/privacy</a> for more information.

Iteos brings Glaxosmithkline a third checkpoint-targeting antibody in a $2B deal

One-on-one with medical innovators: Breakthrough medicines, billion-dollar deals, spectacular clinical successes and crushing failures all play a part in biopharma’s dynamic story. Developers make scientific advancements with the potential to change everything, only to face regulatory conundrums and ever-fluctuating markets. BioWorld tracks key events in the fast-moving sector every business day. Now, the BioWorld Insider podcast lets you hear directly from the movers and shakers whose collective work is changing how we all live. Join us for a new conversation.

Share Iteos brings Glaxosmithkline a third checkpoint-targeting antibody in a $2B deal

Sign up to save your podcasts

Iteos brings Glaxosmithkline a third checkpoint-targeting antibody in a $2B deal

Iteos brings Glaxosmithkline a third checkpoint-targeting antibody in a $2B deal